vs
Side-by-side financial comparison of Adaptive Biotechnologies Corp (ADPT) and AMERICAN SUPERCONDUCTOR CORP (AMSC). Click either name above to swap in a different company.
AMERICAN SUPERCONDUCTOR CORP is the larger business by last-quarter revenue ($74.5M vs $71.7M, roughly 1.0× Adaptive Biotechnologies Corp). AMERICAN SUPERCONDUCTOR CORP runs the higher net margin — 158.1% vs -18.9%, a 177.0% gap on every dollar of revenue. On growth, Adaptive Biotechnologies Corp posted the faster year-over-year revenue change (51.0% vs 21.4%). AMERICAN SUPERCONDUCTOR CORP produced more free cash flow last quarter ($2.4M vs $1.4M). Over the past eight quarters, AMERICAN SUPERCONDUCTOR CORP's revenue compounded faster (33.2% CAGR vs 30.8%).
ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden.
Anglo American plc is a British multinational mining company with headquarters in London, England. It is the world's largest producer of platinum, representing approximately 40 percent of global output, as well as being a major producer of diamonds, copper, nickel, iron ore, polyhalite and steelmaking coal. The company has operations in Africa, Asia, Australia, Europe, North America and South America.
ADPT vs AMSC — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $71.7M | $74.5M |
| Net Profit | $-13.6M | $117.8M |
| Gross Margin | 74.6% | 30.7% |
| Operating Margin | -17.8% | 4.5% |
| Net Margin | -18.9% | 158.1% |
| Revenue YoY | 51.0% | 21.4% |
| Net Profit YoY | 59.7% | 4679.1% |
| EPS (diluted) | $-0.08 | $2.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $71.7M | $74.5M | ||
| Q3 25 | $94.0M | $65.9M | ||
| Q2 25 | $58.9M | $72.4M | ||
| Q1 25 | $52.4M | $66.7M | ||
| Q4 24 | $47.5M | $61.4M | ||
| Q3 24 | $46.4M | $54.5M | ||
| Q2 24 | $43.2M | $40.3M | ||
| Q1 24 | $41.9M | $42.0M |
| Q4 25 | $-13.6M | $117.8M | ||
| Q3 25 | $9.5M | $4.8M | ||
| Q2 25 | $-25.6M | $6.7M | ||
| Q1 25 | $-29.9M | $1.2M | ||
| Q4 24 | $-33.7M | $2.5M | ||
| Q3 24 | $-32.1M | $4.9M | ||
| Q2 24 | $-46.2M | $-2.5M | ||
| Q1 24 | $-47.5M | $-1.6M |
| Q4 25 | 74.6% | 30.7% | ||
| Q3 25 | 80.7% | 31.0% | ||
| Q2 25 | 69.4% | 33.8% | ||
| Q1 25 | 67.6% | 26.5% | ||
| Q4 24 | 62.0% | 26.6% | ||
| Q3 24 | 64.1% | 28.7% | ||
| Q2 24 | 55.3% | 30.3% | ||
| Q1 24 | 56.9% | 24.8% |
| Q4 25 | -17.8% | 4.5% | ||
| Q3 25 | 10.9% | 4.5% | ||
| Q2 25 | -42.5% | 7.8% | ||
| Q1 25 | -56.4% | 2.5% | ||
| Q4 24 | -71.3% | 2.1% | ||
| Q3 24 | -70.3% | -1.4% | ||
| Q2 24 | -109.6% | -8.2% | ||
| Q1 24 | -116.5% | -5.3% |
| Q4 25 | -18.9% | 158.1% | ||
| Q3 25 | 10.2% | 7.2% | ||
| Q2 25 | -43.5% | 9.3% | ||
| Q1 25 | -56.9% | 1.8% | ||
| Q4 24 | -71.0% | 4.0% | ||
| Q3 24 | -69.1% | 9.0% | ||
| Q2 24 | -107.0% | -6.3% | ||
| Q1 24 | -113.5% | -3.8% |
| Q4 25 | $-0.08 | $2.62 | ||
| Q3 25 | $0.06 | $0.11 | ||
| Q2 25 | $-0.17 | $0.17 | ||
| Q1 25 | $-0.20 | $0.04 | ||
| Q4 24 | $-0.22 | $0.06 | ||
| Q3 24 | $-0.22 | $0.13 | ||
| Q2 24 | $-0.31 | $-0.07 | ||
| Q1 24 | $-0.33 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $70.5M | $141.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $218.8M | $536.8M |
| Total Assets | $512.7M | $719.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $70.5M | $141.1M | ||
| Q3 25 | $55.0M | $212.9M | ||
| Q2 25 | $43.2M | $207.9M | ||
| Q1 25 | $50.6M | $79.5M | ||
| Q4 24 | $47.9M | $75.2M | ||
| Q3 24 | $38.1M | $72.1M | ||
| Q2 24 | $59.8M | $93.5M | ||
| Q1 24 | $71.2M | $90.5M |
| Q4 25 | $218.8M | $536.8M | ||
| Q3 25 | $204.4M | $342.2M | ||
| Q2 25 | $179.7M | $333.1M | ||
| Q1 25 | $190.4M | $197.1M | ||
| Q4 24 | $202.7M | $192.7M | ||
| Q3 24 | $223.8M | $187.0M | ||
| Q2 24 | $241.6M | $143.3M | ||
| Q1 24 | $274.9M | $144.6M |
| Q4 25 | $512.7M | $719.5M | ||
| Q3 25 | $490.6M | $445.6M | ||
| Q2 25 | $496.6M | $452.8M | ||
| Q1 25 | $510.9M | $310.5M | ||
| Q4 24 | $539.4M | $310.3M | ||
| Q3 24 | $558.5M | $298.4M | ||
| Q2 24 | $584.9M | $240.1M | ||
| Q1 24 | $620.3M | $232.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.1M | $3.2M |
| Free Cash FlowOCF − Capex | $1.4M | $2.4M |
| FCF MarginFCF / Revenue | 2.0% | 3.2% |
| Capex IntensityCapex / Revenue | 0.9% | 1.2% |
| Cash ConversionOCF / Net Profit | — | 0.03× |
| TTM Free Cash FlowTrailing 4 quarters | $-48.9M | $16.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.1M | $3.2M | ||
| Q3 25 | $-7.1M | $6.5M | ||
| Q2 25 | $-12.4M | $4.1M | ||
| Q1 25 | $-28.5M | $6.3M | ||
| Q4 24 | $-12.5M | $5.9M | ||
| Q3 24 | $-27.1M | $12.7M | ||
| Q2 24 | $-17.3M | $3.4M | ||
| Q1 24 | $-38.4M | $2.2M |
| Q4 25 | $1.4M | $2.4M | ||
| Q3 25 | $-7.5M | $5.1M | ||
| Q2 25 | $-13.1M | $3.3M | ||
| Q1 25 | $-29.7M | $5.3M | ||
| Q4 24 | $-12.6M | $5.3M | ||
| Q3 24 | $-27.4M | $12.1M | ||
| Q2 24 | $-19.0M | $3.1M | ||
| Q1 24 | $-39.9M | $1.9M |
| Q4 25 | 2.0% | 3.2% | ||
| Q3 25 | -8.0% | 7.7% | ||
| Q2 25 | -22.2% | 4.6% | ||
| Q1 25 | -56.7% | 7.9% | ||
| Q4 24 | -26.5% | 8.7% | ||
| Q3 24 | -59.0% | 22.3% | ||
| Q2 24 | -44.1% | 7.8% | ||
| Q1 24 | -95.2% | 4.6% |
| Q4 25 | 0.9% | 1.2% | ||
| Q3 25 | 0.4% | 2.1% | ||
| Q2 25 | 1.1% | 1.1% | ||
| Q1 25 | 2.4% | 1.6% | ||
| Q4 24 | 0.2% | 0.9% | ||
| Q3 24 | 0.7% | 1.1% | ||
| Q2 24 | 4.0% | 0.7% | ||
| Q1 24 | 3.6% | 0.7% |
| Q4 25 | — | 0.03× | ||
| Q3 25 | -0.75× | 1.37× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 5.22× | ||
| Q4 24 | — | 2.38× | ||
| Q3 24 | — | 2.60× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
AMSC
| Equipment And Systems | $56.0M | 75% |
| Megatran | $14.1M | 19% |
| Comtrafo Industria De Transformadores Eletricos SA | $4.6M | 6% |
